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 Abstract 
 Background/Aim: The effect of hypertension on mortality in haemodialysis patients is contro-
versial and can be confounded by non-traditional risk factors like systemic inflammation. This 
study examined the effect of systolic blood pressure (SBP), diastolic blood pressure (DBP), and 
pulse pressure (PP) on mortality in haemodialysis patients, separately with and without markers 
of systemic inflammation.  Methods:  Data from the United States Renal Data System were ana-
lysed for 9,862 patients receiving haemodialysis on December 31, 1993, followed through May 
2005.  Results: In Cox regression analysis, increased age, diabetes, low albumin, high white 
blood count, low cholesterol, low haemoglobin, high phosphate, low DBP, and cardiovascular 
comorbidity were associated with high mortality, but SBP was not. Elevated PP adjusted for SBP, 
age, diabetes, haemoglobin, albumin, cholesterol, calcium, phosphate, parathyroid hormone, 
and white blood count was associated with higher mortality [adjusted hazard ratio, PP 1.006 
(95% confidence interval, CI, 1.002–1.010); SBP 0.993 (95% CI 0.990–0.996)]. In dual models, PP 
adjusted for SBP then DBP was associated with higher mortality [PP 1.029 (95% CI 1.027–1.032); 
SBP 0.981 (95% CI 0.979–0.983); PP 1.010 (95% CI 1.008–1.011); DBP 0.981 (95% CI 0.979–0.983)]. 
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Increasing PP deciles  1 70 mm Hg were associated with increasing mortality in the absence of 
markers of systemic inflammation (white blood count  1 10  ! 10 9 /l, albumin  ! 3.5 g/dl, diabetes), 
but not in their presence.  Conclusion: PP was a better indicator of adverse outcome than DBP 
or SBP. Inflammation-associated injury may mask the effect of PP on mortality in haemodialysis 
patients.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Mortality in patients on maintenance haemodialysis is higher than in the general popu-
lation across all age groups, with cardiovascular cause of death in about 50%  [1] . Thus, obvi-
ous interest is directed towards traditional cardiovascular risk factors. Hypertension, being 
the most prevalent and potentially modifiable traditional cardiovascular risk factor, attracts 
further attention.
 However, the relationship of mortality with hypertension has been controversial. Coun-
terintuitively, in earlier studies a higher systolic blood pressure (SBP) was demonstrated to 
be protective. An SBP  ! 120 mm Hg has been shown to be associated with increased mortal-
ity. Interestingly, the inverse relationship of SBP and mortality persisted even after adjust-
ment for cardiovascular risk factors, hinting perhaps at the possibility of an independent 
strong effect of non-traditional risk factors  [2] .
 Pulse pressure (PP) has been proven to be a better predictor of adverse outcome on hae-
modialysis than diastolic blood pressure (DBP) or even SBP  [3, 4] . PP correlates with central 
arterial stiffness, which has adverse effects on the heart. The stiffness of the central arteries 
increases the cardiac afterload and decreases coronary perfusion  [2] .
 Systemic inflammation, a non-traditional risk factor, is increasingly recognised as a 
powerful contributor to adverse outcomes in patients on maintenance haemodialysis  [5] . The 
subgroup of haemodialysis patients with elevated markers of systemic inflammation tend to 
do poorly. The mechanism of this clinical phenomenon is largely unknown. No study has 
examined the effects of inflammation on the relationship of hypertension with mortality in 
haemodialysis patients.
 The aim of this study was to explore the relationships of SBP, DBP, and PP with all-cause 
mortality in maintenance haemodialysis patients.
 Methods 
 Data from the United States Renal Data System (USRDS) Dialysis Mortality and Mor-
bidity Study (DMMS) Waves 3 and 4 were analysed retrospectively; 9,862 patients undergo-
ing maintenance haemodialysis in the United States in December 1993 were included in the 
study. Baseline demographic information and clinical and laboratory parameters were col-
lected in December 1993. Follow-up data on mortality were available by linking the DMMS 
data set to the USRDS database. Patients were followed till 2005. This retrospective cohort 
was managed very differently from the present patients on maintenance haemodialysis in 
2011 regarding the use of angiotensin-converting enzymes, angiotensin receptor blockers, 
newer phosphate binders, statins, and aggressive cardiovascular screening.
 A mean of three blood pressure readings in the last week of December 1993 was used for 
analysis. Relevant clinical variables at baseline were tested for their relationships with mor-
tality. Variables associated with systemic inflammation, namely diabetes, white blood cell 
count, and low albumin, were included in the model. These markers of inflammation were 
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used due to the absence of better markers, such as C-reactive protein, interleukins, or fibrin-
ogen, in the data.
 We studied the relationship of SBP, DBP, and PP with all-cause mortality, with the aim 
to identify the best measure. The relationships were tested in unadjusted, adjusted, and bi-
variate models. The bivariate models were used to determine the effect of each of the three 
blood pressure variables adjusted for the two others.
 Survival analyses were performed with high and low PP measures (above and below 80 
mm Hg), albumin values (above and below 3.5 g/dl), white blood cell counts (above and be-
low 10  ! 10 9 /l), and presence and absence of diabetes to estimate the unadjusted effect of 
these markers on mortality. These values were predetermined before analysis based on labo-
ratory reporting of normal values; for example, a white cell count of 10 ! 109/l or higher and 
serum albumin less than 3.5 will be considered as abnormal.
 The effect of increased PP on mortality was determined for the entire population and 
then separately in the presence and absence of markers associated with inflammation.
 All statistical analyses were performed using SAS 9.1 (Cary, N.C., USA). Institutional 
approval to perform this study (as part of the operations of the Cardiovascular Special Stud-
ies Center of the USRDS) was obtained from the Hennepin County Medical Center/Minne-
apolis Medical Research Foundation Human Subjects Committee.
 Results 
 The baseline characteristics of the study population ( table 1 ) were similar to the charac-
teristics of the national cohort of dialysis patients at the time of data collection.
 Effect of Baseline Variables on Mortality: Multivariable Analysis 
 The initial multivariate analysis with SBP and DBP, adjusted for age, diabetes, haemo-
globin, albumin, white blood count, calcium, phosphorus, and parathyroid hormone, showed 
no relationship of mortality with SBP and a negative relationship of mortality with DBP ( ta-
ble 2 ). However, PP, adjusted for SBP and all other variables, was associated with increased 
hazards of mortality [adjusted hazard ratio, PP 1.006 (95% confidence interval, CI, 1.002–
1.010); SBP 0.993 (95% CI 0.990–0.996)]. Age and diabetes were strongly associated with mor-
tality in both analyses.
Variable Mean 8 SD 
or percentage
Age, years 59816
Males 51
Diabetes 48
Haemoglobin, g/dl 10.182.3
Albumin, g/dl 3.7680.45
Cholesterol, mg/dl 176847
White blood count, !109/l 7.985.7
Calcium, g/dl 9.382.8
Phosphate, g/dl 6.182.8
Parathyroid hormone, pmol/l 3768766
SBP, mm Hg 152826
DBP, mm Hg 79814
PP, mm Hg 72817
Table 1. C linical characteristics 
of the population
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 Effect of SBP, DBP, and PP on Mortality: Dual Models 
 With bivariate analyses, PP adjusted for SBP and DBP was positively associated with ad-
verse outcome. In the model with SBP and DBP, increased SBP and decreased DBP were as-
sociated with adverse outcomes. PP was again identified as the major determinant of out-
come ( table 3 ).
 Effects of PP and Markers of Inflammation 
 The hazard ratio increases with each 10-mm Hg rise of PP adjusted for age, diabetes, and 
SBP ( fig. 1 ). With Kaplan-Meier survival analysis, a PP  1 80 mm Hg was associated with in-
creased mortality ( fig. 2 ).
 The effect of PP on mortality was attenuated in the presence of the chosen markers of 
systemic inflammation (white blood count  1 10  ! 10 9 /l, albumin  ! 3.5 g/dl, diabetes;  table 4 ). 
Mortality hazard ratios increased significantly for each 10-mm Hg rise of PP  1 70 mm Hg with 
white blood count less than, but not greater than, 10  ! 10 9 /l, from 1.1 at PP 60–69 mm Hg to 
1.8 at PP  1 110 mm Hg. With a similar PP rise (from 60–69 to  1 110 mm Hg) in the absence of 
diabetes, the hazard ratios for mortality increased from 1.1 to 2.2; with albumin  1 3.5 g/dl, the 
hazard ratios increased from 1.1 to 1.8. However, with similar PP changes (from 60–69 to  1 110 
Table 3. D ual models: PP and 
SBP, PP and DBP, and SBP and 
DBP
Variable Hazard ratio
(95% CI)
p
Age 1.037 (1.034–1.040) <0.0001
Diabetes 1.236 (1.147–1.333) <0.0001
Haemoglobin 0.977 (0.958–0.995) 0.0136
Albumin 0.667 (0.667–0.727) <0.0001
Cholesterol 0.998 (0.997–0.999) <0.0001
White blood count 1.005 (1.000–1.010) 0.0355
Phosphate 1.017 (1.007–1.027) 0.0011
Calcium 1.003 (0.990–1.016) 0.6571
Parathyroid hormone 1.000 (1.000–1.000) 0.5546
Coronary heart disease 1.129 (1.041–1.224) 0.0033
Peripheral vascular disease 1.384 (1.267–1.512) <0.0001
Cerebrovascular disease 1.266 (1.145–1.400) <0.0001
Congestive heart failure 1.330 (1.231–1.437) <0.0001
SBP 0.999 (0.996–1.001) 0.2593
DBP 0.995 (0.991–0.999) 0.0220
Table 2. P roportional hazard 
regression: association of 
variables with all-cause 
mortality in haemodialysis 
patients
Variables Mortality hazard ratio 
(95% CI)
Model 1
PP 1.029 (1.027–1.032)
SBP 0.981 (0.979–0.983)
Model 2
PP 1.010 (1.008–1.011)
DBP 0.981 (0.979–0.983)
Model 3
SBP 1.010 (1.008–1.011)
DBP 0.972 (0.969–0.974)
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mm Hg), the changes in hazard ratios were minimal and not statistically significant in the 
presence of diabetes and low serum albumin. This apparent ‘nullification’ of PP as an inde-
pendent predictor of mortality was most evident with regard to diabetes. For example, in non-
diabetic (‘non-inflamed’) patients with PP 90–99 mm Hg (compared to 60–69 mm Hg), the 
hazard ratio was 1.61 (95% CI 1.40–1.84), versus 0.93 (95% CI 0.81–1.07) in diabetic patients. 
In patients with comparable PP (90–99 mm Hg), the hazard ratio for those with lower white 
blood cell count (‘non-inflamed’) was 1.41 (95% CI 1.27–1.56), versus 1.04 (95% CI 0.81–1.37) 
for patients with higher white blood cell count; the hazard ratio for patients with higher serum 
albumin was 1.46 (95% CI 1.30–1.63), versus 1.15 (95% CI 0.97–1.38) for patients with lower 
 Fig. 1. Hazard ratios for mortality for each 10-mm 
Hg rise of PP adjusted for age, diabetes, and SBP. 
 Fig. 2. Survival for patients with PP above and be-
low 80 mm Hg. 
Table 4. E ffect of markers of systemic inflammation on the relationship of PP and mortality
PP 
mm Hg
M ortality hazard ratio (95% CI)
no diabe tes white blood count
<10!109/l
albumin 
>3.5 g/dl
diabetes white blood count
>10!109/l
albumin 
<3.5 g/dl
<50 0.976 (0.859–1.109) 0.940 (0.842–1.050) 0.899 (0.790–1.023) 0.992 (0.825–1.192) 1.028 (0.773–1.366) 1.018 (0.856–1.211)
50–59 1.000 1.000 1.000 1.000 1.000 1.000
60–69 1.113 (1.005–1.232) 1.111 (1.021–1.208) 1.106 (1.007–1.215) 0.930 (0.819–1.055) 0.889 (0.714–1.108) 1.055 (0.914–1.217)
70–79 1.279 (1.156–1.414)* 1.191 (1.097–1.293)* 1.193 (1.089–1.308)* 0.953 (0.845–1.076) 1.210 (0.916–1.489) 1.246 (1.086–1.430)
80–89 1.484 (1.326–1.660)* 1.375 (1.259–1.501)* 1.418 (1.286–1.563)* 0.998 (0.881–1.138) 1.138 (0.916–1.413) 1.205 (1.040–1.396)
90–99 1.608 (1.403–1.844)* 1.406 (1.268–1.559)* 1.457 (1.301–1.633)* 0.931 (0.808–1.071) 1.039 (0.808–1.336) 1.154 (0.967–1.377)
100–109 2.034 (1.695–2.440)* 1.583 (1.387–1.805)* 1.702 (1.472–1.968)* 1.021 (0.862–1.210) 1.460 (1.076–1.981) 1.323 (1.065–1.644)
>110 2.231 (1.711–2.908)* 1.806 (1.495–2.180)* 1.765 (1.444–2.157)* 1.155 (0921–1.448) 1.397 (0.951–2.052) 1.812 (1.323–2.483)
* p < 0.0001.
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serum albumin. At the highest PP ( 1 110 mm Hg), there was a two-fold mortality hazard for 
non-diabetic patients and no significant mortality hazard for diabetic patients. In contrast, a 
significant mortality hazard was present for patients with this markedly elevated PP irrespec-
tive of serum albumin or white blood count, suggesting a possible qualitative difference in 
diabetes compared with the other inflammatory markers, particularly in patients with severe 
atherosclerotic disease (as manifested by the markedly abnormal PP).
 Discussion 
 This study aimed to establish the role of PP on mortality in a large cohort of haemodi-
alysis patients. Interestingly, we found that PP loses its effect on mortality in the presence of 
systemic inflammation.
 We found that PP appears to be a better predictor of adverse outcomes than SBP in pa-
tients on maintenance haemodialysis. As expected, DBP was shown to be a negative predic-
tor of mortality. The findings correlate with large studies of US and Japanese haemodialysis 
patients  [3, 4] . This study thus reinforces the importance of arterial stiffness as a marker of 
adverse outcomes, as shown in a French haemodialysis population, and PP as a clinical mark-
er of central arterial stiffness  [6, 7] .
 We examined the effect of a non-traditional risk factor, systemic inflammation, on the 
relationship of PP with mortality, as systemic inflammation has recently been proposed to 
be a significant marker of vascular ill health and adverse outcomes in patients with kidney 
disease  [8] . Systemic inflammation is related to atherosclerosis and hence to increased car-
diovascular event rates. We hypothesised that this effect of systemic inflammation on car-
diovascular events and cardiovascular mortality would be stronger than the effect of de-
creased vascular compliance.
 Our study found that the effect of PP on mortality was nullified by rising markers of 
systemic inflammation. Though PP exhibits an effect on mortality due to arterial stiffness, 
in the presence of markers of inflammation, namely high white blood cell count, low albu-
min, and diabetes, this effect is lost as the ill effects of systemic inflammation become over-
whelming. High white cell count is a crude but well-established marker of systemic inflam-
mation. White blood cell count is perhaps less sensitive than C-reactive protein, interleukins, 
or fibrinogen; however, in our large dialysis cohort we believe that its clinical significance is 
important. White cell count as a marker of inflammation has been proven to be a predictor 
of cardiovascular disease  [9] . A study of haemodialysis patients showed a relationship be-
tween white blood cell count and C-reactive protein over time  [10] . In the same study, serum 
albumin levels steadily improved with decreasing C-reactive protein  [10] . This evidence sug-
gests that systemic inflammation is associated with low albumin as part of a negative acute-
phase reaction. Diabetes is now recognised to be associated with low-grade inflammation 
related to its pathogenesis and as a cause of target organ injury. Inflammatory pathways im-
pede insulin activity and predispose to diabetes  [11] . However, diabetes can affect vascular 
function in several pathways, and some of these are independent of inflammation.
 The adverse effects of systemic inflammation could be related to both atherosclerotic and 
non-atherosclerotic cardiovascular diseases. In the general population, inflammation pro-
motes atherosclerosis by causing endothelial dysfunction. Endothelial dysfunction is present 
and associated with inflammation in patients on haemodialysis. Cardiac fibrosis due to local 
inflammation in the heart could be another mechanism related to systemic inflammation. It 
is well known that sudden cardiac death related to cardiomyopathy and arrhythmia is a com-
mon cause of death in patients on haemodialysis  [12] . Evidence from obser vational studies 
suggests an increase in sudden cardiac death with rising C-reactive protein  [13] .
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 Our study has limitations. As mentioned above, the lack of information on C-reactive 
protein, interleukins, or fibrinogen as markers of inflammation is a definite disadvantage. 
White cell count has been used in other studies but is a less sensitive marker of inflamma-
tion, and serum albumin is a negative acute-phase reactant but could decrease due to mal-
functioning of the liver. Diabetes-related target organ injury is associated with low-grade 
inflammation, but not always. Due to the nature of the study data, which are from a large 
database, we also lacked information on a linear relationship between PP and mortality. The 
study was retrospective and hence there are limitations as regards to information on the 
change of risk factor profile with time. The changes in the risk factor profile with time can 
change the outcome significantly. In addition, lack of echocardiographic data on ejection 
fraction limits the interpretation of systolic function and its relationship with PP and mor-
tality. The extent of atherosclerosis is unknown and hence cannot be related to either tradi-
tional or non-traditional risk factors. The white cell count and serum albumin may change 
with time, and our study measured it at baseline only. This limits accurate assessment of the 
effects of such measures on the outcome.
 However, the study generates an important hypothesis regarding the effect of non-tra-
ditional risk factors on the relationship of mortality and traditional risk factors in patients 
on maintenance haemodialysis. Traditional risk factors cause vascular damage in early 
chronic kidney disease and before dialysis initiation. The contribution of inflammation to 
cardiovascular damage may be slight at this stage of chronic kidney disease. Once the in-
flammation has progressed after dialysis initiation, its effect on endothelial dysfunction, 
atherosclerosis, and cardiomyopathy may become overwhelming and hence traditional risk 
factors become less significant. Such a hypothesis needs to be proven with prospective fol-
low-up studies, preferably with intervention.
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